Skip to main content

Asterand to Validate Abcam’s Antibodies

NEW YORK (GenomeWeb News) – Asterand said today that it will validate and characterize antibodies and immunohistochemistry applications for antibody marketer Abcam.

Under the collaborative agreement, Asterand will use its PhaseZero Human Tissue Services platform and its Target Evaluator gene expression database to select antibodies and to identify expression patterns for their use with human tissue.

The resulting data will be incorporated into Abcam’s literature and technical support documentation for each antibody tested and will be sold through its online catalogue.

Abcam’s scientific director, Mark Bushfield, said in a statement that Asterand “will quickly identify suitable tissues for testing and rapidly determine dilutions and concentrations for use with human tissue. “

Financial terms of the agreement were not released.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.